KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) Equity Average (2017 - 2025)

Historic Equity Average for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $40.5 million.

  • Co-Diagnostics' Equity Average fell 4054.51% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 4054.51%. This contributed to the annual value of $70.2 million for FY2024, which is 3002.39% down from last year.
  • As of Q3 2025, Co-Diagnostics' Equity Average stood at $40.5 million, which was down 4054.51% from $44.5 million recorded in Q2 2025.
  • Co-Diagnostics' Equity Average's 5-year high stood at $146.1 million during Q2 2022, with a 5-year trough of $40.5 million in Q3 2025.
  • In the last 5 years, Co-Diagnostics' Equity Average had a median value of $92.8 million in 2023 and averaged $92.1 million.
  • Per our database at Business Quant, Co-Diagnostics' Equity Average soared by 58385.21% in 2021 and then plummeted by 4092.27% in 2025.
  • Co-Diagnostics' Equity Average (Quarter) stood at $117.3 million in 2021, then grew by 6.32% to $124.7 million in 2022, then fell by 25.64% to $92.8 million in 2023, then crashed by 36.34% to $59.0 million in 2024, then tumbled by 31.44% to $40.5 million in 2025.
  • Its Equity Average stands at $40.5 million for Q3 2025, versus $44.5 million for Q2 2025 and $51.1 million for Q1 2025.